Bergen, Norway, 16 June 2021 - Reference is made to the stock exchange notice
published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 11 June 2021 where
the Company announced that the board of directors of the Company had resolved to
increase the Company's share capital in connection with the exercise of options
pursuant to the Company's share option program. A total of 75,000 options were
exercised and 75,000 new shares were issued at an average subscription price of
NOK 10.62 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company's share capital
is NOK 8,796,275.50 divided into 87,962,755 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.